After two years of deliberations the Pharmaceutical Benefits Advisory Committee (PBAC) on Friday formally rejected an application by drug manufacturer MSD Australia and New Zealand to have ...
Clinical Senior Lecturer at Deakin University School of Medicine & Pain Specialist, Barwon Health Australia’s oxycodone problem has thankfully not risen to the heights of the public health disaster ...